CCM
GILD icon

CrestPoint Capital Management’s Gilead Sciences GILD Stock Holding History

CrestPoint Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-4,300
Closed -$435K – 225
2015
Q4 		$435K Sell
4,300
-6,100
-59% -$635K 0.25% 125
2015
Q3 		$1.02M Buy
+10,400
New +$1.16M 0.59% 61

Other funds holding GILD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

CrestPoint Capital Management's GILD Position: Q1 2016 in Review

CrestPoint Capital Management sold out of Gilead Sciences (GILD) in Q1 2016, closing a stake of 4,300 shares — an estimated $435K sold.

CrestPoint Capital Management first reported a position in GILD in Q3 2015 and held it in 2 quarters. The position peaked at $1.02M in Q3 2015. 1,630 funds tracked by Wall St. Rank hold GILD as of Q1 2016.

  • CrestPoint Capital Management reported no remaining Gilead Sciences position as of Q1 2016 after selling out during the quarter.
  • CrestPoint Capital Management sold 4,300 Gilead Sciences shares in Q1 2016, an estimated $435K.
  • CrestPoint Capital Management first reported a position in Gilead Sciences in Q3 2015 and held it in 2 quarters.
  • CrestPoint Capital Management's Gilead Sciences position peaked at $1.02M in Q3 2015.
  • 1,630 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2016.

Based on CrestPoint Capital Management's 13F filing for Q1 2016, filed 15 Apr 2016.